First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer

Oncology
Se Hoon ParkJae Hoon Lee

Abstract

The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma. Patients with histologically proven advanced colorectal adenocarcinoma received a first-line chemotherapy with irinotecan 240 mg/m2 on day 1 and capecitabine 2,000 mg/m2/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Treatment was repeated every 3 weeks. Thirty-nine patients were registered, and 36 were assessable for responses. Sixteen objective responses (44%) were observed with a median response duration of 6.9 months. Stable disease was documented in 14 cases (39%). The median time to progression was 6.7 months. The median overall survival was not reached at the time of analysis, and the 1-year survival rate was 67%. Two patients died: 1 due to sepsis not complicating myelosuppression, and 1 patient, known as a hepatitis B virus carrier prior to chemotherapy, died of hepatic failure, the cause of which was not clinically verified. Frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea. Severe hand-and-foot syndrome was observed in only 1 patient. The combin...Continue Reading

Citations

Feb 23, 2010·Diseases of the Colon and Rectum·Kelly R FinanJames W Fleshman
Dec 12, 2007·International Journal of Clinical Oncology·Katsuto Shinohara
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alexandre AlanioJean Menotti
Apr 26, 2008·The Journal of Antimicrobial Chemotherapy·Theresa S RichardsTheodore C White
Apr 14, 2007·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Joshua M BerlinRobert A Sarro
Dec 8, 2007·Chemotherapy·F MeriggiA Zaniboni
Mar 2, 2012·Chemotherapy·Andreas HochstrasserMartin Früh
Oct 27, 2007·Neurosurgical Focus·Andrew D NordenPatrick Y Wen
Jan 17, 2012·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Sang Hoon ChunHoon-Kyo Kim
Mar 4, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Melike Ceyhan Balcı ŞengülKemal Kaya
Aug 8, 2008·Future Oncology·Andrew J RothChristian J Nelson
Mar 4, 2014·Journal of the National Cancer Institute·Emma ErikssonLars Sävendahl
Aug 4, 2011·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Soon LeeWon Ki Kang
Jul 12, 2005·Expert Opinion on Investigational Drugs·Kenneth KhamlyJohn Zalcberg
Mar 19, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Raquel Duque Nascimento ArifaDanielle Glória Souza
Nov 3, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C S VoicanR Coriat
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neal J MeropolRoland Schwarting
Feb 16, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W ReaC J A Punt
Dec 22, 2005·The Oncologist·Richard M Goldberg
May 21, 2017·International Journal of Clinical Oncology·Koji AndoUNKNOWN Kyushu Study Group of Clinical Cancer (KSCC)

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.